Illumina's products and services are low-cost, high-value with good accuracy, which have, therefore, become the operating system for diagnostic tests in genomic and personalized medicine. The company provides a line of products and services that serve the sequencing, genotyping, and gene expression markets. Its customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. The company's tools allow researchers worldwide to perform genetic tests needed to extract valuable medical information from advances in genomics and proteomics. In January 2007, Illumina completed the acquisition of Solexa, which develops and commercializes genetic analysis technologies used to perform a range of analyses including whole genome resequencing, gene expression analysis, and small RNA analysis.